Company Profile

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâ€™s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Employees

Sector

Investment Holding Companies

More about the company

16/12/24	Histogen Inc. Went Out of Business	CI
02/12/24	Modified First Amended Liquidation Plan Approved for Histogen Inc.	CI
30/09/24	First Amended Liquidation Plan Filed by Histogen Inc.	CI
30/08/24	Bankruptcy Judge Changed for Histogen Inc.	CI
14/07/24	Liquidation Plan Filed by Histogen Inc.	CI
19/04/24	Subchapter V Trustee Appointed Under Chapter 11 for Histogen Inc.	CI
18/04/24	Histogen Inc. Filed for Bankruptcy	CI
10/11/23	Histogen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
04/10/23	Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index	CI
03/10/23	Histogen Inc. and Allergan Mutually Elect to Terminate the Amended and Restated License Agreement	CI
22/09/23	Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index	CI
20/09/23	Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	MT
20/09/23	Top Premarket Gainers	MT

29/03/22	HC Wainwright Adjusts Histogen's Price Target to $1.50 From $2.40, Reiterates Buy Rating	MT
30/08/21	Histogen : HC Wainwright Starts Histogen at Buy With $2.40 Price Target	MT
04/06/21	Histogen : Canaccord Genuity Adjusts Histogen PT to $4 From $5, Maintains Buy Rating	MT
04/06/21	Histogen : Canaccord Genuity Adjusts Histogen's Price Target to $4 From $5, Reiterates Buy Rating	MT
04/03/21	Histogen : Canaccord Genuity Initiates Coverage on Histogen at Buy Rating, Sets Price Target at $5	MT

19/04/24	Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering	AQ
15/12/23	Histogen Announces Second Adjournment of Special Meeting of Stockholders	AQ
06/12/23	Histogen Announces Adjournment of Special Meeting of Stockholders	AQ
10/11/23	Histogen: Q3 Earnings Snapshot	AQ
18/09/23	Histogen Announces Board Approval of Complete Liquidation and Dissolution	AQ

06/07/23	MÄRKTE USA/Schwächer - Robuste Wirtschaftsdaten treiben Zinsen nach oben
06/07/23	MÄRKTE USA/Stark steigende Zinsen schicken Aktien auf Talfahrt
06/07/23	MÄRKTE USA/Schwach - Robuster US-Arbeitsmarkt befeuert Zinssorgen
06/07/23	MÄRKTE USA/Zinssorgen dürften drücken - ADP-Daten belasten Renten
04/04/23	MÄRKTE USA/Wall Street mit leichten Aufschlägen

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/20/23 A	David Crean	Free	Chairman	6,835	0.1600%
6/20/23 A	Dan Kisner	Free	Chairman	6,835	0.1600%
6/20/23 A	Jonathan Jackson	Free	Director	6,835	0.1600%

Histogen Inc. Stock

Stocks

HSTO.Q

US43358Y2028

Investment Holding Companies

Chart: Histogen Inc.

Latest news : Histogen Inc.

Analysts' recommendations: Histogen Inc.

Press Releases: Histogen Inc.

News in other languages: Histogen Inc.

Quotes and Performance

Latest insider transactions

Shell Companies

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HISTOGEN INC.	+316.67%	+525.00%	-	-	5.34K
CHURCHILL CAPITAL CORP XI	-6.71%	-9.82%	-	-	813M
CENTIEL AG	-3.24%	-4.65%	+297.58%	-71.97%	668M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	-0.10%	-	-	645M
CHURCHILL CAPITAL CORP XII	-0.74%	0.00%	-	-	595M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.59%	+0.59%	-	-	602M
CANTOR EQUITY PARTNERS IV, INC.	-0.10%	-0.29%	-	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.26%	-0.86%	-	-	569M
CHURCHILL CAPITAL CORP XIII	-0.10%	-0.38%	-	-	507M
Average	+34.01%	-1.94%	+297.58%	-71.97%	624.05M
Weighted average by Cap.	-1.60%	-2.33%	+297.58%	-71.97%